LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

Inicio・Lista de Acciones・United Therapeutics Corp

United Therapeutics Corp

Abierto

SectorSanidad

547.1 -0.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

543.92

Máximo

550.22

Métricas clave
By Trading Economics
Ingresos	-89M 275M
Ventas	-8.7M 782M
P/B Media del Sector	20.134 49.888
BPA	5.82
Margen de beneficios	35.176
Empleados	1,400
EBITDA	-176M 348M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+21.1% upside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.5B 23B
Apertura anterior	547.14
Cierre anterior	547.1

Noticias sobre sentimiento de mercado

By Acuity

50%

139 / 344 Clasificación en Healthcare

United Therapeutics Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 19:20 UTC

Principales Movimientos del Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 jun 2026, 23:36 UTC

Charlas de Mercado

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 jun 2026, 18:00 UTC

Ganancias

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 jun 2026, 12:40 UTC

Adquisiciones, fusiones, absorciones

Correction to Texas Billionaires Article America's Resort -- WSJ

6 jun 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Adquisiciones, fusiones, absorciones

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Ganancias

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Charlas de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Charlas de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Charlas de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Charlas de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Adquisiciones, fusiones, absorciones

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Ganancias

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

United Therapeutics Corp previsión

Precio Objetivo

By TipRanks

21.1% repunte

Estimación a 12 Meses

Media 665.9 USD 21.1%

Máximo 738 USD

Mínimo 516 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para United Therapeutics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para United Therapeutics Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

139 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.